These results sparked an interest in HER2-low BC, with numerous studies reporting on its prognosis [4], analytical difficulties [5], change of HER2 status [6], and biology of HER2-low disease at the genomic and transcriptomic level [7]. This evidence concerns the gene ERBB2 and breast cancer.